Vienomics is a pioneer in early-stage cancer detection and the first Chinese company to commercialize genomic liquid biopsy testing services for cancer screening. Vienomics began with a simple idea – to detect cancer early and proactively treat cancer at a curable stage. Being on the cutting edge of transforming cancer diagnosis is more than an ambition. The work we do every day saves tens of thousands of real lives and families. Our proprietary digital sequencing technology with unprecedented breadth and depth enables us to get a precise picture of the individual genomic alterations associated with development and progression of cancer. At Vienomics, we believe it is our responsibility to deliver the most reliable and accurate results. That’s why we established strict quality system with the international leading level. We are collaborating with top community and academic medical centers to conduct clinical studies to confirm the clinical validity and utility of our products.